Sirtuin Biology in Cancer and Metabolic Disease

Kenneth Maiese, MD, is an internationally recognized physician-scientist whose investigations are designed to translate basic science into successful therapeutic treatments. He maintains therapeutic and scientific expertise in multiple medical disciplines and has been fortunate to receive recognition with outstanding teaching and investigator awards, election to America’s Top Physicians and The Best of U.S. Physicians, recipient of Albert Nelson Marquis Lifetime Achievement Award, and elected as an America’s Health Insurance Plans (AHIP) Executive Leadership Fellow. His work has received the distinction of “High Impact Research and Potential Public Health Benefit” by the National Institutes of Health. As an internationally recognized physician researcher and “C-suite” healthcare leader, he has extensive experience in academic medicine, healthcare delivery, business development, managed care, biotechnology, and drug development holding positions as member and advisor for the National Institutes of Health Biotechnology and Venture Capital Development, National Institutes of Health Innovation Network, Chief Medical Officer, tenured Professor and Chair and Chief of Service of the Department of Neurology and Neurosciences of Rutgers University, Global Head of Translational Medicine and External Innovation, Board Member of the Cancer Institute of New Jersey, Steering Committee Member for the Foundation for the National Institutes of Health, tenured Professor in Neurology, Anatomy & Cell Biology, Molecular Medicine, the Barbara Ann Karmanos Cancer Institute, and the National Institute of Health Center at Wayne State University, and Founding Editor and Editor-in-Chief of multiple highly successful international journals.

• Preface Section I: Sirtuins and metabolic disease 1. Sirtuins in metabolic disease: innovative therapeutic strategies with SIRT1, AMPK, mTOR, and nicotinamideKenneth Maiese2. Sirtuins in metabolic and epigenetic regulation of stem cellsYi Fang and Xiaoling Li 3. Sirtuins and metabolic regulation: food and supplementationSérgio Henrique Sousa Santos, Victor Hugo Dantas Guimarães, Janaina Ribeiro Oliveira, and Luiz Fernando Rezende 4. Sirtuins in diabetes mellitus and diabetic kidney diseaseKultigin Turkmen 5. Sirtuins and mitochondrial dysfunctionJian-Li He, Tian-Shi Wang, and Yi-Ping Wang 6. Sirtuins in immunometabolismHongxiu Yu 7. Mitochondrial sirtuins at the crossroads of energy metabolism and oncogenic transformationMaja Grabacka and Przemyslaw M. Plonka Section II: Sirtuins and cancer 8. Sirtuins and the hallmarks of cancerTalita H.B. Gomig, Tayana S. Jucoski, Erika P. Zambalde, Alexandre L.K. Azevedo, Daniela F. Gradia, and Enilze M.S.F. Ribeiro 9. The bifunctional roles of sirtuins and their therapeutic potential in cancerYeuan Ting Lee, Yi Jer Tan, Pei Yi Mok, Ayappav. Subramaniam, and Chern Ein Oon 10. Sirtuins and next generation hallmarks of cancer: cellular energetics and tumor promoting inflammationRobert Kleszcz and Wanda Baer-Dubowska 11. Sirtuins and cellular metabolism in cancersZhen Dong and Hongjuan Cui 12. Dual role of sirtuins in cancerMargalida Torrens-Mas and Pilar Roca 13. Sirtuin signaling in hematologic malignanciesRyan A. Denu 14. Impacts of sirtuin1 and sirtuin3 on oral carcinogenesisShajedul Islam, Yoshihiro Abiko, Osamu Uehara, Yasuhiro Kuramitsu, and Itsuo Chiba Index